Horizon Discovery to Collaborate with Novartis | GenomeWeb

NEW YORK (GenomeWeb News) – Horizon Discovery and Novartis have struck a collaboration for cancer models that will be used in Novartis' drug research programs.

Cambridge, UK-based Horizon Discovery said this week that under the four-year strategic collaboration it will use its Genesis gene engineering platform to develop a panel of genetically defined mutant and normal (X-MAN) cancer models for the drug company. In return, Novartis will pay Horizon up-front, milestone, and renewal fees of undisclosed value.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.